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Abstract
Subjective alertness and optimal cognitive function, including in terms of attention, spatial/working memory and executive 
function, are intrinsic to peak performance in many sports. Consumption of a number of plant-derived ‘secondary metabolite’ 
phytochemicals can modulate these psychological parameters, although there is a paucity of evidence collected in a sporting 
context. The structural groups into which these phytochemicals fall—phenolics, terpenes and alkaloids—vary in terms of 
the ecological roles they play for the plant, their toxicity and the extent to which they exert direct effects on brain function. 
The phenolics, including polyphenols, play protective roles in the plant, and represent a natural, benign component of the 
human diet. Increased consumption has been shown to improve cardiovascular function and is associated with long-term 
brain health. However, whilst short-term supplementation with polyphenols has been shown to consistently modulate cerebral 
blood-flow parameters, evidence of direct effects on cognitive function and alertness/arousal is currently comparatively weak. 
Terpenes play both attractant and deterrent roles in the plant, and typically occur less frequently in the diet. Single doses of 
volatile monoterpenes derived from edible herbs such as sage (Salvia officinalis/lavandulaefolia) and peppermint (Mentha 
piperita), diterpene-rich Ginkgo biloba extracts and triterpene-containing extracts from plants such as ginseng (Panax gin-
seng/quinquefolius) and Bacopa monnieri have all been shown to enhance relevant aspects of cognitive function and alert-
ness. The alkaloids play toxic defensive roles in the plant, including via interference with herbivore brain function. Whilst 
most alkaloids are inappropriate in a sporting context due to toxicity and legal status, evidence suggests that single doses of 
nicotine and caffeine may be able to enhance relevant aspects of cognitive function and/or alertness. However, their benefits 
may be confounded by habituation and withdrawal effects in the longer term. The efficacy of volatile terpenes, triterpene-
rich extracts and products combining low doses of caffeine with other phytochemicals deserves more research attention.
Key Points 
Evidence collected in normal healthy samples suggests 
that secondary metabolite phytochemicals from each of 
the main structural groups—phenolics (polyphenols), 
terpenes and alkaloids—may result in improvements to 
cognitive function and psychological state that could be 
relevant to sports performance.
A lack of research collected in the context of sporting 
performance limits the extent to which these results can 
inform practical recommendations.
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1  Cognitive Function Relevant to Sporting 
Performance
Optimal cognitive functioning is essential for peak sport-
ing performance. Indeed, aspects of cognitive function 
enjoy a bi-directional relationship with sporting activ-
ity. Whilst the evidence is not entirely unequivocal [1, 
2], some research suggests that athletes outperform non-
athletes in terms of tasks measuring processing speed 
and attention [3], executive function [4], and spatial and 
working memory [5], but that different types of regular 
sporting activity with dissimilar cognitive requirements 
can be associated with corresponding differences in the 
performance of cognitive tasks measuring, for instance, 
attention task performance [3], executive function [4] and 
working memory capacity [6].
A common-sense case could clearly be made for the 
intrinsic contribution of efficient brain function, for 
instance in cognitive domains such as attention (which 
incorporates psychomotor-speed/reaction-times), spatial/
working memory and executive function, to all forms of 
sporting performance. Clearly the comparative contribu-
tion of each domain would be dependent on the demands 
of differing sports [1, 3, 4, 6]. Similarly, modulation of a 
subjective psychological state, particularly increased alert-
ness and decreased mental fatigue, will naturally have a 
knock-on effect on cognitive function, motivation and 
performance. All of these aspects of cognitive function 
and psychological state are amenable to modulation by the 
consumption of selected plant-derived ‘phytochemicals’.
Unfortunately, there is a complete absence of research 
assessing the psychoactive properties of most phytochemi-
cals in a sporting context. There is also a lack of research 
investigating how and to what extent an improvement in 
any specific aspect of cognitive function or psychological 
state will result in improved sporting performance. Even 
for caffeine, which has benefitted from substantial relevant 
research, there is a paucity of research assessing the contri-
bution that improved alertness and attention, as opposed to 
caffeine’s direct effects on physical performance, make to 
its beneficial effects on sporting performance (see Goldstein 
et al. [7]). As there are very few data collected in a sporting 
context, the following necessarily comprises a brief review 
of the evidence for potentially relevant cognitive/mood 
improvements drawn from the wider human controlled-trial 
literature. Whilst it seems reasonable to assume that the find-
ings from this body of research would apply at least equally 
in a sporting context, the possibility that the increased physi-
ological activation, psychological arousal or social interac-
tions involved in some sports might have an interactive rela-
tionship with the psychological effects of phytochemicals 
has not been empirically investigated.
2  Phytochemicals
As rooted, stationary autotrophs, each genus or species of 
plant has evolved the capacity to synthesise a unique mixture 
of ‘phytochemicals’. These ‘secondary metabolites’ play no 
role in the plant’s primary metabolism and have no macro-
nutrient nutritional value. However, their synthesis increases 
the plant’s overall ability to overcome local challenges, by 
allowing the plant to interact with its environment. The roles 
here encompass general protection (e.g. antioxidant, ultra-
violet light-absorbing and anti-proliferative properties); 
management of the plant’s relationship with pathogenic 
and symbiotic microorganisms above and below the soil; 
defence against local competitor plants; and management 
of the plant’s relationship with more complex organisms 
[8–10]. The latter includes both the deterrence of herbivory 
and attraction of pollinators and other symbiotes via colour 
and volatile chemical emissions. The primary relationships 
in these latter categories are with insects, the most abundant 
and prolific family of animals and the plant’s most intimate 
and co-evolved neighbour both in terms of herbivory and 
pollination. In this regard, it is relevant that, courtesy of 
a shared genetic heritage, insects and humans share func-
tionally similar nervous systems, including in terms of all 
aspects of neurotransmission and cellular signal transduction 
mechanisms and molecules [8–10].
Most secondary metabolite phytochemicals can be clas-
sified into one of three structural groups: phenolics, terpe-
nes and alkaloids. These groups play different ecological 
roles in the plant. Phenolics are present in all plant mate-
rial where they play primarily protective roles in the face of 
environmental stressors. They provide colour, antioxidant 
and antimicrobial protection, particularly in the outer layers 
of leaves, fruits, etc. Terpenes play dual roles depending on 
the plant tissue and mode of delivery: the lower molecular 
weight volatile terpenes act as attractants for pollinators or 
symbiotes at low, airborne doses, but as toxic deterrents at 
the higher concentrations found in plant tissue and on the 
surface of leaves. More complex terpenes tend more towards 
toxic deterrence, including via interactions with the nerv-
ous and hormonal systems of potential herbivores. The last 
structural group, alkaloids, play almost exclusively toxic 
roles, again potentially via direct interactions with the nerv-
ous systems of herbivores [8–10].
These differing ecological roles correspond in many 
ways with the functional effects of these structural groups 
in human consumers. Phenolics, a ubiquitous component of 
the human diet, will tend towards exerting a global, benefi-
cial effect on human physiological function, whereas both 
terpenes and alkaloids have evolved to exert multifarious 
direct, purposeful interactions with the nervous systems of 
symbiotic or herbivorous animals. This latter property can 
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translate into an ability to modulate human brain function 
in the short term.
3  Phenolics
The most intensively studied group of phytochemicals, the 
‘phenolics’, can be broadly divided into simple phenolics, 
which incorporate one phenyl aromatic hydrocarbon ring 
within their structure and polyphenols, which incorporate 
two aromatic rings [11]. Each group can be further subdi-
vided, with most polyphenols falling into the flavonoid sub-
group, which can be further sub-divided into the chalcones, 
the flavanones and their derivatives the flavones, flavonols, 
isoflavones, flavanols and anthocyanins [12]. The flavanols 
comprise the most complex and varied sub-class of flavonoid 
structures, which range from single molecules (monomers), 
such as catechin and epicatechin, to chains of two (dimers) 
or more (oligomers/polymers) molecules, which are often 
referred to as proanthocyanidins or condensed tannins [13]. 
Unlike the small monomers (and some dimers), which can 
be absorbed in the upper intestine, the more complex struc-
tures first have to undergo metabolism by gut microbiota 
prior to absorption, and often ultimately appear in the cir-
culation in the form of simple phenolics.
Polyphenols are present in most plant materials and are an 
unavoidable part of the human diet, with the greatest quanti-
ties being consumed in the form of alcoholic and non-alco-
holic beverages such as wine and tea, fruit and fruit juices, 
and vegetables [14]. However, food diary studies suggest a 
wide variability in flavonoid consumption. For instance, the 
populations of the USA, Spain, Australia and France have 
been estimated to consume approximately 190 mg, 310 mg, 
450 mg and 550 mg of flavonoids per day, respectively, with 
the largest part being taken in the form of flavanols and their 
oligomers and polymers [14–16]. Although receiving less 
attention, simple phenolics tend to be consumed at higher 
levels than polyphenols [17, 18].
Although polyphenols are typically described as antioxi-
dants, the current consensus is that their effects are attribut-
able to direct interactions within cellular signal transduc-
tion pathways [9, 19]. Functional effects here can include 
direct interactions with cellular receptors, but are more 
likely predicated on interactions within the protein-kinase 
and lipid-kinase signalling cascades [e.g. mitogen-activated 
protein kinase (MAPK) and phosphatidylinositide 3-kinase/
protein kinase B (PI-3K/PKB)] that ferry signals received 
from outside of the cell, often by membrane or nuclear 
receptors, towards the cell’s nucleus. Targets also include 
cellular signal collection and processing mechanisms such as 
the ubiquitous energy-regulating target of rapamycin (TOR), 
which collects and rationalises information about external 
conditions, and internal energy availability and expenditure 
from multiple cellular signal transduction cascades [9, 
20–23]. The summed and interacting activity in these signal 
transduction pathways dictate the cell’s response to environ-
mental, stressor or internal energy-related information, for 
instance by modulating the activity of transcription factors 
[e.g. nuclear factor kappa-B (NF-kB) or cAMP response 
element-binding protein (CREB)]. This in turn leads to a 
wide range of cellular responses, including cell proliferation, 
apopotosis, the synthesis of growth factors and inflammatory 
molecules such as ‘induced’ nitric oxide synthase (iNOS), 
cytokines and cyclo-oxygenase-2 (COX-2). Overactivity or 
dysregulation within these signalling pathways is implicated 
in the pathogenesis of cardiovascular and neurodegenera-
tive diseases and cancers [22, 24]. Interestingly, most of the 
mammalian cellular effects of polyphenols take place in the 
components of cellular signal-transduction cascades that 
are encoded by the ~ 3000 conserved genes that plants and 
humans share [9].
Of particular relevance to the brain, these signal transduc-
tion effects encompass, for instance: direct neurotransmitter 
receptor interactions; an increase in the synthesis of the neu-
rotrophins that are integral to synaptic plasticity; and interac-
tions with the ‘receptor tyrosine kinase’ membrane recep-
tors that transduce neurotrophin signals, and their signalling 
cascades [25]. Interactions within kinase and TOR signalling 
pathways also modulate the synthesis of the vasodilatory 
molecule nitric oxide, leading to an increase in local cerebral 
blood flow, which in turn fosters angiogenesis/neurogenesis. 
These, and the more general cellular effects of phenolics, 
may contribute to both short-term benefits to brain function 
and neuroprotection/neuronal repair in the face of ageing 
and insults [21, 22, 26].
Whilst nitric oxide synthesis may partially underpin 
short-term cardiovascular benefits, polyphenols have also 
been shown to attenuate the inflammation and oxidative 
stress implicated in the pathogenesis of cardiovascular 
disease and tumorogenesis [27], and the neuronal damage 
associated with neurodegenerative diseases and the dete-
rioration in cognitive function seen with ageing [28]. One 
further mechanism that is coming under increasing scrutiny 
is the role of dietary phenolics in the modulation of the gut 
microbial communities (which play a bi-directional role in 
cardiovascular and brain function)—a role that mirrors their 
management of nutrient-absorbing, symbiotic microbial 
populations in the plant’s root system [8, 9].
In line with these mechanistic effects, epidemiological 
evidence suggests that dietary phenolic consumption con-
fers a wide range of health benefits. For example, individual 
cohort studies and multiple meta-analyses of the body of 
epidemiological research show that the consumption of 
polyphenols or polyphenol-rich foods is inversely related 
to all aspects of cardiovascular disease, including mortal-
ity [29–34]; protection against cerebrovascular diseases 
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and neurological disorders, including dementia [35–42]; 
improved cognitive function in healthy middle age [43]; 
and reduced cognitive impairment and cognitive decline in 
elderly populations [36, 38, 44–46].
The cardiovascular benefits have also been confirmed 
in a large body of controlled intervention trials, princi-
pally involving polyphenols derived from cocoa, which are 
described briefly below. This having been said, the direct 
evidence of benefits related to physical performance or phys-
iological parameters in recreational, competitive or elite ath-
letes is currently insufficient to arrive at any conclusion as to 
the efficacy of polyphenol supplements in this regard [47].
The literature relating to several of the sources of poly-
phenols and individual compounds that have garnered sig-
nificant amounts of relevant human research in non-sporting 
contexts are described below.
3.1  Cocoa Flavanols
The largest body of human polyphenol research has involved 
the administration of cocoa-derived products, which are par-
ticularly rich in the flavanols catechin and epicatechin and 
their dimers/oligomers. Research here has benefitted from 
the availability of several standardised high-flavanol prod-
ucts. To date there is a lack of research assessing the effects 
of cocoa-flavanols on brain function in a sporting context 
[48], with the exception of a recent study that reported inde-
pendent improvements in executive function following 30 
min of moderate intensity cycling and a high cocoa-flavanol 
(536 mg flavanols) drink [49]. However, this study did not 
measure cognitive function during exercise or relate this to 
any aspect of performance.
Meta-analyses of the data from many dozens of inter-
vention trials demonstrate a consistent beneficial effect of 
cocoa-flavanols on cardiovascular parameters, including 
inflammatory biomarkers related to atherosclerosis, insu-
lin resistance, lipid profiles, blood-pressure and peripheral 
blood flow as measured by flow-mediated dilatation (FMD) 
[32, 50–52]. These meta-analyses suggest that these effects 
are achievable with an optimal dose of ~500 mg of flavanols 
per day [52] and within 2 h of consumption of the first dose 
[53]. It should be noted that many cocoa-derived products 
contain some carbohydrates, and almost all contain poten-
tially bioactive levels of caffeine and other alkaloid methyl-
xanthines. However, controlled trials typically match their 
comparator control interventions for these components.
In terms of brain function, increases in cerebral blood-
flow (CBF) have been seen following single doses of 
cocoa extract containing ~ 500 mg [54] and 900 mg [55] 
of flavanols, using functional magnetic resonance imag-
ing (fMRI) and trans-cranial Doppler (TCD), respectively. 
Cocoa extracts containing 170 mg [56] and 450 mg [57] 
of flavanols, administered sub-chronically for 5 days and 
2 weeks, respectively, also increased CBF in healthy older 
and younger adults as assessed by fMRI and near-infrared 
spectroscopy (NIRS). Only one study has failed to report any 
CBF effects to date, in this case following both a single dose 
and 4 weeks’ administration of a low-caffeine cocoa extract 
containing 250 mg flavanols in comparison to a caffeine-free 
control [58].
In terms of psychological function following single doses, 
controlled crossover trials have demonstrated improvements 
on cognitively demanding tasks and reduced mental fatigue 
following the lower of two single doses of cocoa-flavanols 
(520 mg/994 mg) [59], and improved spatial memory, choice 
reaction time and visual sensitivity following flavanol-
enriched dark chocolate (720 mg) [60]. One study also 
reported improved performance on a focussed attention task 
following brewed cocoa containing 500 mg of flavanols and 
20 mg of caffeine versus a caffeine-free placebo [61], and 
one study reported no effects following cocoa drinks con-
taining 250 mg and 500 mg of flavanols [62].
With regards chronic dosage, the best evidence of ben-
efits comes from a pair of methodologically identical stud-
ies carried out in 90 healthy elderly participants [63] and 
90 sufferers from age-related cognitive impairment [64], 
respectively. In both studies, participants received a low 
(control), medium (520 mg) or high (990 mg) flavanol 
drink for 4 weeks. In both studies the high-flavanol drink 
was associated with reduced insulin resistance, blood pres-
sure and lipid peroxidation, and improved performance on 
two cognitive tasks that assessed attention and executive 
function. These findings were mirrored by those following 
the medium-flavanol treatment, with the exception that this 
dose did not improve the attention task. These findings are 
supported by a study also undertaken in 40 elderly partici-
pants in which supplementation with 500 mg of flavanols for 
12 weeks resulted in improvements on a composite cognitive 
score derived from a battery of tasks. In this study, blood 
levels of brain-derived neurotrophic factor (BDNF), a pro-
tein involved in the survival, growth and differentiation of 
new neurons and synapses in the brain, were also increased 
in the flavanol condition [65].
Whilst these studies look promising, several studies 
involving the administration of 250–750 mg of flavanols for 
4–6 weeks to middle-aged/older participants have failed to 
elicit any relevant improvements in cognitive function or 
psychological state [62, 66, 67]. It may be relevant that only 
one of these null studies reported matching the caffeine lev-
els in their control treatments [62].
3.2  Fruit Polyphenols
Fruit polyphenol interventions typically contain a complex 
mixture of simple phenolics and polyphenols. Compara-
tor interventions in this research are typically matched for 
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carbohydrate content if necessary. Whilst no studies have 
assessed the effects of fruit polyphenols on sporting perfor-
mance, increases in CBF as assessed by arterial spin label-
ling fMRI have been seen in healthy adults, in comparison to 
a control, following a single dose of orange juice containing 
70 mg of flavonoids [68] and after 12 weeks’ administration 
of a blueberry extract containing 387 mg of anthocyanidins 
[69]. A previous study also demonstrated increased brain 
activation (fMRI) and memory task performance, alongside 
increased plasma biomarkers of polyphenol absorption, in 
middle-aged and older participants following 4  weeks’ 
administration of pomegranate juice [70].
In terms of studies assessing psychological functioning, 
several crossover studies in healthy adults have reported 
subtle, treatment-related differences in cognitive function 
following single doses. For instance, two crossover studies 
involving the administration of anthocyanin-rich fruit juice 
containing 500 mg [71] and 140 mg [72] of anthocyanins 
reported benefits that were restricted to the performance of 
attention tasks, with the latter study also reporting improved 
subjective ratings of calmness. One study [73] found that 
orange juice (272 mg of flavanones) improved one of two 
psychomotor ‘finger tapping’ tasks and one attention task 
(out of nine tasks) and increased alertness. However, stud-
ies involving single doses of orange juice containing 70 mg 
of flavanones [68] and flavonoid-rich homogenised apple 
(360 mg of flavonoids) [74] found no significant differences 
compared with their control arms.
Two chronic dosage crossover studies have also been 
reported. In one [75], high (305 mg) versus low (37 mg) 
flavanone orange juice administered for 8 weeks to 37 older 
adults resulted in subtle improvements on one global meas-
ure of cognitive function performance. However, grape juice 
containing 770 mg of polyphenols consumed for 12 weeks 
by a small cohort of healthy working mothers did not result 
in any readily interpretable cognitive, mood or driving task 
benefits [76]. Two small studies also assessed the cogni-
tive effects of blueberry drinks containing 143 mg [77] and 
125/250 mg of anthocyanins [78] in children, with only 
the latter study demonstrating mild dose-related cognitive 
benefits.
3.3  Single Molecule Polyphenols: Resveratrol, 
Curcumin and Quercetin
Resveratrol and curcumin are both non-flavonoid poly-
phenols (a stilbene and a curcuminoid, respectively) that 
are regularly consumed as single compounds. On the 
basis of preclinical and animal research it has been sug-
gested that resveratrol has a number of properties relevant 
to the enhancement of physical or sporting performance, 
although this has not been investigated in humans to date 
[79]. This polyphenol has been shown to improve peripheral 
blood-flow, as assessed by FMD, in overweight/obese 
humans following a single dose and extended supplementa-
tion [80, 81]. Similarly, single doses of resveratrol (250 mg 
and 500 mg) have been shown to increase CBF in the frontal 
cortex during task performance in healthy young adults, as 
assessed by NIRS [82–84]. Single doses of 75 mg, 150 mg 
and 300 mg also increased CBF responses during hyper-
capnia in type II diabetics as assessed with TCD [85], with 
the lowest dose also increasing the haemodynamic response 
to cognitive task performance [86]. However, across these 
single-dose CBF studies only one reported concomitantly 
improved cognitive function, and this was restricted to two 
out of three doses of resveratrol [86].
In terms of chronic supplementation studies, 75 mg of 
resveratrol administered for 14 weeks to post-menopausal 
women resulted in an increased haemodynamic response 
to both hypercapnia and cognitive task performance as 
measured with TCD, alongside a general improvement in 
cognitive task performance [87]. Two placebo-controlled 
studies also assessed the effects of 26 weeks’ supplementa-
tion with resveratrol (200 mg/day) in 46 older adults [88] 
and 40 older adults with mild cognitive impairment [89]. 
Both studies demonstrated increased hippocampal connec-
tivity as assessed by fMRI, but only the cognitively intact 
cohort saw cognitive improvements in the form of improved 
memory performance [88]. In contrast, Wightman et al. [82] 
demonstrated a lack of any interpretable cognitive effects of 
28 days’ supplementation with 500 mg resveratrol, although 
subjective fatigue was reduced. A recent meta-analysis 
reported beneficial effects of resveratrol on cognitive func-
tion [90]. However, only three studies out of the ten that 
were included in the analysis reported benefits, and two of 
these three studies administered resveratrol alongside other 
polyphenols (red wine and quercetin, respectively).
Meta-analyses of the results of multiple human trials sug-
gest that curcumin, the principal polyphenol found in tur-
meric, can improve serum lipid levels [91], gluco-regulation 
[92] and inflammatory cytokine levels [93], and that it may 
be effective in treating depression [94]. Recent studies have 
suggested protective anti-inflammatory properties in the face 
of exercise-induced muscle damage [95] and preservation of 
gastrointestinal barrier damage during heat stress exercise 
[96]. Interestingly, a recent study demonstrated that 8 weeks’ 
supplementation with curcumin in the absence of exercise 
resulted in a similar improvement in endothelial function to 
a programme of aerobic exercise alone [97].
There is less evidence with regard cognitive function, 
and no studies that have been conducted in a sporting con-
text. In one study in older adults, both a single dose and 4 
weeks’ administration of 400 mg of curcumin led to mod-
estly improved cognitive function in terms of attention and 
working memory, with additional improvements in fatigue 
or alertness either before or after the day’s treatment after 
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4 weeks [98]. In the only other study involving healthy 
humans [99], there were no interpretable beneficial cognitive 
or mood effects of 12 months’ administration of 1500 mg 
of curcumin.
Evidence suggests that chronic consumption of the fla-
vonoid quercetin may have a small beneficial effect on 
endurance exercise (at around 1 g per day) in humans [100], 
although the evidence is somewhat equivocal [47]. How-
ever, whilst there is some evidence of improved cognitive 
functioning following this single-molecule polyphenol in 
rodents, only one study has assessed psychological func-
tioning in humans, with no effect of 12 weeks’ supplementa-
tion seen in a large sample of young, middle-aged and older 
adults [101].
3.4  Other Polyphenols
Several other polyphenol groups have attracted some 
research attention in this area. A review of studies assess-
ing the cognitive effects of estrogenic soy-isoflavones [102] 
described equivocal evidence across 11 studies, mainly in 
samples of post-menopausal women. Similarly, whilst a 
number of studies have assessed the effects of chronic sup-
plementation with proanthocyanidin-rich pine bark extracts, 
the evidence of benefits in psychological functioning, to 
date, is less than clear [103–106].
3.5  Conclusion
The epidemiological and meta-analysis evidence that sug-
gests wide-ranging cardiovascular benefits associated with 
consuming polyphenols is credible and consistent. However, 
the case for benefits to cognitive performance or psychologi-
cal states relevant to sport performance is less persuasive. 
There is clear evidence that polyphenol-rich products con-
sistently increase CBF or modulate brain activity after single 
doses [54, 55, 68, 83–85, 107] and longer periods of sup-
plementation [56, 57, 69, 70, 88, 108, 109]. However, whilst 
most of these CBF studies included an assessment of cogni-
tive task performance or mood, only a very small minority 
[70, 86, 88] reported any significant improvements in these 
domains in comparison to placebo. In contrast, slightly more 
than half of the above studies that focussed solely on cogni-
tive function and psychological state reported interpretable 
benefits in comparison to placebo. However, the benefits in 
several of these papers could best be described as subtle. 
This does suggest the potential for a publication bias within 
the literature in this area. Either way, the current evidence 
base suggests significant physiological health benefits for the 
consumption of polyphenols at levels that can be achieved 
in the diet, but the evidence with regard to the potential for 
phenolic supplements to improve aspects of cognitive func-
tion or psychological state relevant to sport performance in 
the short term is currently equivocal. Further research into 
the medium-/long-term effects of supplementation with phe-
nolics is warranted.
4  Terpenes
The terpenes comprise a large, structurally diverse family of 
35,000 + compounds that are composed of units of the vola-
tile, organic, 5-carbon compound isoprene, and classified 
according to the number of isoprene units they contain. The 
lower molecular weight volatile monoterpenes and sesquiter-
penes incorporate two and three isoprene units, respectively, 
whereas diterpenes, triterpenes and tetraterpenes incorpo-
rate four, six and eight units, respectively [11]. All plants 
synthesise terpenes, both as primary metabolites and as the 
principle volatile components of the gaseous emissions, such 
as floral bouquets, that attract pollinators and symbiotes. 
However, only a minority of plant clades have evolved the 
specific use of terpenes in extensive ecological roles, such 
as defence against herbivory [8].
4.1  Monoterpenes/Sesquiterpenes
A number of plant families rely on volatile terpenes not only 
as airborne attractants, but also as defensive agents [8, 110]. 
As attractants, plants synthesise and release comparatively 
low concentrations of mono- and sesquiterpenes. Many of 
these volatile terpenes are also produced endogenously by 
insects as intra-species (pheromone) and inter-species (allo-
mone) communication chemicals [111]. When employed in a 
defensive role, the same volatile terpenes are typically man-
ufactured and stored at high concentrations in cells external 
to the plant’s vascular system in order to avoid auto-toxic-
ity. For instance, they can be synthesised in tiny stalk cells, 
called glandular trichomes, on the insect-favoured underside 
of the leaf, and stored in a balloon-like bladder on top of the 
stalk [112]. When a herbivore visits the plant the delicate 
bladders are broken open, delivering a toxic dose of sticky, 
terpene-rich oil onto the visitor. The key difference between 
attraction and toxicity is therefore the dose and mode of 
administration of the volatile terpenes. Indeed, the lower, 
airborne doses of volatile terpenes that are associated with 
attraction will not negatively affect insect neurotransmission 
and behaviour, and may have a beneficial effect, as befits 
their roles as insect pheromone/allomone chemicals. The 
higher, defensive doses will, on the other hand, interfere 
with the same aspects of neurotransmission [8].
The dual use of volatile terpenes in ecological roles is 
particularly prevalent within the large Lamiaceae family of 
plants. The Nepetoideae sub-family represents a particu-
larly abundant source of monoterpene-rich culinary herbs 
and essential oils, which are distilled oils composed of the 
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plant material’s volatile terpenes. In line with this, essential 
oils contained in the trichomes of plants from across this 
taxon generally exhibit dose-dependent insecticidal proper-
ties against adult insects, principally via interactions with 
the insect nervous system [113], and they kill and inhibit 
the growth of larvae from a number of species [114, 115].
Most of the psychoactive members of Nepetoideae, 
including rosemary, lemon balm, sage and peppermint, 
belong to the Mentheae tribe of plants. Essential oils from 
this group typically contain mono- and sesquiterpenes such 
as 1,8-cineole, α-pinene camphor, geraniol, geranial, bor-
neol, camphene and β-caryophyllene [116, 117], with the 
differing aromas of family members being due to the dif-
fering concentrations of these. So, for instance, rosemary 
essential oil typically comprises 60% 1,8-cineole whereas 
peppermint primarily expresses menthol and menthone 
[118]. These plants also express comparatively low concen-
trations of diterpenes and triterpenes, but reasonably high 
levels of phenolics, including, in all cases, rosmarinic acid 
and its derivatives, alongside other phenolic acids and poly-
phenols [119–124].
Extracts from this family of plants share common (but 
variable) mechanisms of action relevant to the brain, for 
instance, inhibiting acetylcholinesterase and binding allos-
terically to gamma-aminobutyric  acidA  (GABAA), nicotinic 
and muscarinic receptors [8]. For some of these mechanisms 
of action their overall potency depends on synergistic inter-
actions between their monoterpene constituents [125–127]. 
These mechanistic effects do mean that some members of 
this plant group would be unlikely to have beneficial effects 
on cognitive function in a sporting context. The obvious 
examples here are Melissa officinalis (lemon balm) extracts, 
which exert  GABAA [128] and nicotinic/muscarinic receptor 
binding and cholinesterase inhibitory properties that depend 
on the nature of the extract [126, 129–131]. Research in 
healthy adults shows that lemon balm extracts can improve 
aspects of cognitive function [129, 130, 132], but that they 
can equally result in decreased alertness, increased fatigue 
and some cognitive decrements [130–132], depending both 
on the dose and the nature of the extract.
There is a lack of research into the effects of volatile ter-
penes in a sporting context [48]. Only the Mentheae that 
have resulted in consistent, potentially relevant psychologi-
cal benefits will be considered below.
Interestingly, volatile terpenes, which are small lipophilic 
molecules, have been shown to have rapid bioavailability 
following passive inhalation and pulmonary absorption of 
vapour [133, 134]. It is also likely that purposeful intra-
nasal inhalation of concentrated volatile terpenes confers 
a number of further brain bioavailability advantages, with 
additional absorption via the nasal cavity’s olfactory and 
epithelium mucosa [135] and potential intraneural and peri-
neural transport along the trigeminal nerve and olfactory 
tract to a number of brain regions, including the piriform 
and entorhinal cortices, amygdala and hypothalamus [135]. 
Whilst passive inhalation has been investigated (e.g. Moss 
et al. [136, 137]—see section 4.1.2) the advantage of pur-
poseful nasal inhalation in terms of brain function has not 
yet been investigated.
4.1.1  Sage (Salvia officinalis/lavandulaefolia)
The psychoactive effects of consuming single doses of cho-
linesterase inhibiting sage extracts have been assessed in 
a series of double-blind, placebo-controlled, crossover tri-
als in healthy humans. The two lowest of four single doses 
(167/333/666/1333 mg) of an ethanolic extract of S. offici-
nalis containing a full range of phytochemicals improved 
memory task performance in healthy elderly adults over 
the 6 h following consumption, with the lowest dose also 
improving attention task performance [138]. Similarly, both 
300 mg and 600 mg of encapsulated dried sage improved 
mood in young adults, with the lower dose reducing anxiety 
and the higher dose improving subjective ratings of alertness 
and calmness [139].
Several studies have assessed the effects of essential oils 
composed solely of the volatile terpenes present in plant 
material in young adults. In the first of these the consump-
tion of single doses of 50 µl and 100 µl of encapsulated 
S. lavandulaefolia essential oil [140] improved memory 
task performance over 2.5 h post dose. These effects were 
replicated following single doses of 25 µl and 50 µl of the 
same essential oil, along with improved performance of 
a working memory/executive function task and improved 
levels of subjective alertness, calmness and contentment 
[141]. Most recently, the psychoactive properties of cho-
linesterase inhibiting S. lavandulaefolia essential oil were 
confirmed in healthy young adults who consumed single 
doses of 50 µl oil composed exclusively of monoterpenes 
and with a high concentration of 1,8-cineol. Within the first 
4 h, memory and attention task performance were improved 
alongside increased alertness and reduced mental fatigue 
during extended performance of difficult tasks [142]. One 
parallel-groups study has also assessed the cognitive and 
mood effects of S. officinalis and S. lavandulaefolia essen-
tial oil vapour versus a no-vapour control condition [143]. 
In these ‘aromatherapy’ studies, participants are exposed to 
vapour in a small enclosed room, with the volatile terpenes 
absorbed through the lungs and mucosa. In this instance, 
both sage vapours improved mood, but only S. officinalis 
improved memory performance in healthy young adults.
4.1.2  Rosemary (Rosmarinus officinalis)
Whilst the analgesic and antispasmodic effects of rose-
mary extracts may be due to GABA, opioid, muscarinic or 
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serotonin (5-HT) receptor interactions [144–146], the psy-
choactive properties of rosemary may relate to cholinergic 
receptor binding and cholinesterase inhibitory properties 
[147–149].
A handful of studies have assessed the effects of rosemary 
on human brain function. In the earliest study, exposure to 
vaporised rosemary essential oil increased alertness and led 
to more accurate but slower memory task performance, in 
comparison to a control condition, in 140 young healthy 
participants [136]. This study was followed by two studies 
involving 20 and 64 participants in which plasma levels of 
1,8-cineole were seen to increase alongside increased expo-
sure to essential oil vapour, confirming the bioavailability 
of the monoterpenes via inhalation. The changes in perfor-
mance of attention, working memory/executive function 
tasks [137] and a prospective memory task [150] also cor-
related with plasma levels of 1,8-cineole post administration.
Several randomised, double-blind studies have also 
assessed the effects of oral consumption of rosemary. In 
the first crossover study, 28 elderly adults consumed single 
oral doses of 750/1500/3000/6000 mg of powdered rose-
mary leaf on separate occasions. Assessments across the 
next 6 h showed improvements in alertness and the speed 
of performing memory tasks following the lowest dose, but 
significant decrements on the same measures following the 
highest dose, with mixed results for the intermediate doses 
[122]. Subsequently, a single-dose crossover study in 40 
young adults demonstrated no effects of 1.7 g of dried rose-
mary leaf on a single sustained attention task and subjec-
tive ratings of psychological state [151]. One study has also 
assessed the effects of longer term consumption (4 weeks) 
of 500 mg of dried rosemary in 68 healthy young adults 
and found that the participants’ subjective ratings of their 
prospective and retrospective memory performance, anxi-
ety and depression improved when taking rosemary. In this 
instance no objective measures of cognitive function were 
taken [152].
4.1.3  Peppermint (Mentha piperita)
Peppermint typically expresses high levels of the monoterpe-
nes menthol and menthone [153, 154]. In vitro, essential oils 
and/or menthol alone have cholinesterase inhibitory proper-
ties [153, 155, 156] and interact with 5-HT3 [157],  GABAA 
[158–160] and glycine [158] receptors.
In one of two single-blind studies, peppermint tea 
increased alertness and improved accuracy and speed of 
memory task performance 20 min after consumption, in 
comparison to a hot water control, in 180 young adults [161]. 
In the second, the only study to date involving physical per-
formance, pure peppermint essential oil dripped onto the 
tongue improved auditory and visual reaction times 5 min 
and 1 h after administration and improved lung function and 
physical performance (grip force, standing vertical and long 
jump) in comparison to a water control in 30 participants 
[162]. In the only double-blind, placebo-controlled study 
to date [118], 24 participants received 50 µl and 100 µl of 
encapsulated peppermint essential oil and placebo on sepa-
rate occasions. In this instance, the essential oil had been 
selected on the basis of its in vitro ability to inhibit cho-
linesterase and bind to nicotinic and  GABAA receptors, with 
increased cellular activity confirmed in a neuronal cell line. 
Consumption of the highest dose of essential oil resulted in 
improved performance of a focussed attention task at 1 and 
3 h post dose, and improved serial subtraction task perfor-
mance and reduced mental fatigue at 3 h post dose. These 
effects had attenuated by 6 h post dose.
4.2  Diterpenes
Most psychoactive diterpenes have an assumed provenance 
as insecticidal feeding deterrents. Examples include tanshi-
nones from Salvia miltiorrhiza, which exert GABAergic 
and cholinesterase inhibitory properties, picrotoxin from 
Anamirta cocculus, which is a potent inhibitor at  GABAA 
receptors, and the hallucinogenic κ-opioid receptor agonist 
salvinorin A from Salvia divinorum [8].
4.2.1  Ginkgo biloba
The only contenders within this structural group with regard 
to evidence of relevant improvements in human cognitive 
function are the diterpene ginkgolides and their bilobalide 
derivatives from Ginkgo biloba. There is, however, a lack of 
evidence collected in a sporting context [48]. Interestingly, 
ginkgolides have potent insecticidal properties via GABA 
receptor inhibition, but mammals are spared this functional 
effect by a tiny, single amino-acid divergence in the mor-
phology of our genetically conserved GABA receptor [163]. 
Ginkgolides and bilobalide typically make up 6% of stand-
ardised G. biloba extracts.
The vast bulk of the large research effort surrounding 
G. biloba extracts has focussed on dementia. Meta-anal-
yses of the data from the many trials in this area suggest 
that G. biloba extracts exert promising effects with regard 
to cognitive function and behaviour in this patient group 
[164–168], although the evidence is not altogether unequivo-
cal [169–171].
In healthy populations, standardised G. biloba extracts 
have been shown to increase CBF in brain-imaging stud-
ies following 4 weeks’ [172] and 8 months’ [173] supple-
mentation. A number of randomized control trials have also 
demonstrated cognitive enhancement, including in terms of 
attention task performance, in young adults following single 
doses of G. biloba extract [174–179], and in both younger 
[180] and older [181–183] ‘cognitively intact’ populations 
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administered G. biloba for 7 days or longer. More recent 
studies employing larger samples, and focussing on healthy 
middle-aged participants, have shown improved memory 
performance after 6 weeks’ supplementation in 188 partici-
pants [184], and improved attention, memory and subjective 
ratings of physical health in 300 participants administered 
G. biloba for 12 weeks [185].
4.3  Triterpenes
Triterpenes play diverse ecological roles for the synthesis-
ing plant, including pronounced anti-feedant/anti-herbivore 
and soil-micro-organism management roles. Many of these 
functions are potentially related to the triterpene chemical 
structure, which is also the favoured structure for hormonal 
communications across phyla. Examples include mammalian 
sex hormones (estrogen/testosterone) and glucocorticoids 
(cortisol), invertebrate hormones, insect ecdysteroids and 
plant brassinosteroids. These structural similarities allow 
plant triterpenes to interfere with ecdysteroid function and 
therefore the life cycle of herbivorous insects [8], and poten-
tially disrupt the endocrine function of invertebrates [186]. 
They also interact with pathogenic and symbiotic soil micro-
organisms via bacterial/fungal ‘estrogen-like’ receptors [8].
Many triterpene-containing herbal extracts are tradition-
ally classified as ‘adaptogens’, a term that denotes that they 
primarily function by protecting the consuming organism 
from the negative impact of physical, biological, chemi-
cal and psychological stress. Typically they are theorised 
to do this by fostering homeostasis in the face of stressors 
by modulating the functioning of the hypothalamic–pitui-
tary–adrenal (HPA) axis [187]. In this regard, a number 
of these triterpenes have been shown to interact with mul-
tiple mammalian steroid hormone receptors [188]. As an 
example, ginsenosides and their metabolites exert measur-
able in vivo effects on many aspects of HPA axis function 
and interact directly at multiple steroid hormone receptors 
including ubiquitous estrogen and glucocorticoid receptors 
[188]. Similarly, plant-derived phytoecdysteroids, which 
mimic the structure of insect hormones, are available as 
body-building supplements, and they have their effects on 
mammalian muscle mass via interactions with mamma-
lian nuclear hormone receptors [189]. The global effects 
of interactions with the ubiquitous glucocorticoid receptor 
alone could encompass many of the diverse physiological 
effects of this class of phytochemicals, including effects on 
neurotransmission.
4.3.1  Ginseng (the Panax genus)
The active components of ginseng (members of the Panax 
genus) extracts comprise 40 or more triterpene ‘ginseno-
sides’ [190]. Many of the physiological effects of ginseng 
can be accommodated by modulation of nitric oxide synthe-
sis [190, 191]. For instance, Panax ginseng has been shown 
to have greater utility in treating ischemic heart disease than 
nitrates [192], and is an effective treatment for erectile dys-
function [193]. In contrast, whilst the ergogenic effects of 
ginseng have been investigated in numerous studies, the evi-
dence to date is equivocal, potentially due to methodological 
issues within this literature [194, 195].
Nitric oxide synthesis may be one consequence of either 
the genomic or non-genomic effects of modulating the glu-
cocorticoid system, as described in Sect. 4.3. These nuclear 
receptor interactions may also underpin the multifarious 
effects relevant to brain function, which include indirect 
modulation of  GABAA, serotonin, nicotinic and glutamate 
N-methyl-d-aspartic acid (NMDA) receptor function, and 
modulation of cellular signal transduction [188, 196].
In terms of human brain function, only one double-blind, 
parallel-groups study assessed psychological functioning in 
a sporting context, demonstrating improved reaction times 
on a psychomotor task both before and during graded cycle 
ergometer exercise in a small sample of 15 athletes [197].
In a non-sporting context a number of randomised, con-
trolled, balanced-crossover, single-dose (200–400 mg) trials 
have demonstrated consistent improvements in the accuracy 
of memory tasks [198–200] and the speed of attention task 
performance [200, 201]. Single doses have also decreased 
the latency of cerebro-electrical evoked potentials as meas-
ured by electroencephalography (EEG) [202], and improved 
the performance of difficult working memory/executive 
function tasks and concomitantly reduced mental fatigue 
[203, 204]. A recent study [205] also showed that 7 days’ 
supplementation increased ‘calmness’, following both doses 
investigated (200/400 mg), and improved performance of the 
‘3-back’ working memory task following the higher dose, 
but with slower performance following the lower dose. A 
subsequent study assessing the effects of 8 weeks’ admin-
istration of a Korean red ginseng extract also demonstrated 
improved working memory performance and modulation of 
ratings of ‘calmness’ [206]. A single study has also extended 
these findings to single doses of a standardised Panax 
quinquefolius extract, with demonstrations of improved 
working memory performance and dose-dependent increases 
in speed of performance [207].
4.3.2  Bacopa monnieri
The active constituents of Bacopa monnieri extracts are trit-
erpene bacosides or bacopasides that are structurally similar 
to the ginsenosides [208, 209]. Whilst the exact mechanisms 
by which Bacopa modulates brain function remain unclear, 
animal research suggests interactions with the acetylcholine, 
opioid and GABA neurotransmitter systems [210–214] and 
the HPA axis [215].
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In humans, whilst some research has assessed the acute 
cognitive and mood effects of bacopa [216, 217], none of 
this has taken place in a sporting context. A recent meta-
analysis of the data from nine chronic dosage (> 12 weeks) 
randomised, controlled trials, incorporating 518 participants, 
found that supplementation with ~ 300 mg/day of bacopa 
extract (containing 50% triterpene bacosides) improved 
attention-task performance and speed of processing [218]. 
One of the included studies also demonstrated a decreased 
latency of evoked potentials to stimuli (i.e. faster cerebro-
electrical processing) using EEG [219].
4.3.3  Other Triterpenes
Several other triterpene-rich herbal extracts have exhibited 
potentially relevant effects in humans. A meta-analysis of 
data from 11 studies in which Centella asiatica (Gotu kola) 
extracts, which contain triterpene asiaticosides, were admin-
istered for 60 days or more, either alone or in combination, 
demonstrated no effects on cognitive function, but signifi-
cant increases in subjective alertness and calmness [220]. 
Similarly, an Avena sativa (wild green oat) extract contain-
ing triterpene avenacins has also been shown to improve 
peripheral and cerebral vasodilation in healthy participants 
[221] after 12 weeks’ supplementation with 1500 mg. A 
single dose (800 mg) of the same extract also increased 
the global speed of performing computerised tasks, and 
improved working memory and executive function task 
performance, in the 6 h after consumption. In this instance 
a higher dose (1600 mg) was less effective [222]. Single, 
placebo-controlled studies also demonstrated that Withania 
somnifera extract, which contains triterpene withanolides, 
administered for 60 days could improve attention, executive 
function and memory [223], and that Rhodiola rosea extract, 
which contains salidrosides, could increase the speed and 
accuracy of two attention tasks [224].
4.4  Conclusion
Terpene phytochemicals have a number of specific brain 
function effects predicated on their dual ecological roles as 
insect attractants and/or deterrents. Monoterpenes derived 
from a number of edible and well tolerated herbs, particu-
larly terpene-rich sage, rosemary and peppermint, have been 
shown to exert a number of potentially beneficial effects on 
human cognitive function and alertness/fatigue that would 
be relevant to sporting performance. Amongst the more 
complex non-volatile terpenes, diterpene-rich G. biloba 
extracts and several triterpene containing extracts also show 
some promise. In particular, single doses of standardised 
ginseng (P. ginseng/quinquefolius) extract and chronic sup-
plementation with B. monnieri extracts have been shown 
to consistently improve cognitive function across several 
domains relevant to sport. However, there is a paucity of 
research assessing either the chronic effects of ginseng or the 
acute effects of B. monnieri, therefore no conclusion can be 
reached with regards these dosing regimens.
5  Alkaloids
Alkaloids are a structurally diverse group of low molecular 
weight compounds that contain one or more nitrogen atoms, 
typically as part of an amine group. They are synthesised by 
approximately 20% of plant species, almost all of which are 
flowering plants. They play exclusively defensive ecologi-
cal roles, most notably by protecting plants against herbivo-
rous insects and invertebrates via toxicity. In this respect, 
interference with all aspects of neurotransmission is one of 
their hallmark functions. Because of the close similarities 
between insect, invertebrate and mammalian nervous sys-
tems, plant-derived alkaloids (sometimes slightly modified) 
provide us with numerous psychoactive compounds, includ-
ing medicines, deliriants and most of our social and illicit 
drugs: nicotine, caffeine, cocaine, opiates, amphetamine and 
its many derivatives, and hallucinogens such as mescaline, 
psilocin and lysergic acid diethylamide (LSD). Given their 
toxicity, legal status and psychopharmacological properties, 
few alkaloids would confer any potential benefits in a sport-
ing context, potentially with the exception of the two most 
commonly consumed psychoactive compounds: nicotine and 
caffeine.
5.1  Nicotine
The brain function effects of nicotine are predicated on its 
excitatory binding to acetylcholine nicotinic receptors. The 
subsequent modulation of glutamatergic and GABAergic 
function leads to the release of other neurotransmitters, with 
dopamine driving nicotine’s addictive properties, GABA and 
β-endorphins mediating anxiolytic properties, noradrenaline 
contributing to the arousing effects, 5-HT driving mood 
effects, and 5-HT, dopamine and noradrenaline all serving 
to reduce appetite [225–227].
Regular nicotine use will create addiction and habitua-
tion, whereby nicotinic receptor populations and sensitiv-
ity change over time, leading to symptoms of withdrawal 
in nicotine’s absence. Much of the human literature is 
therefore confounded by conducting research in smokers 
who had abstained from smoking, making the interpreta-
tion of any net effects of nicotine difficult to disentangle 
from alleviation of decrements due to being in a state of a 
withdrawal. However, whilst there is plentiful evidence of 
nicotine exerting cardiovascular effects potentially relevant 
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to improved physical performance in nicotine-naïve con-
sumers [228], this evidence is not matched by any persua-
sive evidence of actual performance improvements [228, 
229]. The story with regard to brain function in a non-
sporting context is better. A comprehensive meta-analysis 
included the data from 50 methodologically adequate stud-
ies that had assessed the effects of nicotine administered 
via various methods in non-deprived smokers, minimally 
deprived smokers or non-smokers. The authors concluded 
that, irrespective of nicotine withdrawal, nicotine led to 
consistent improvements in cognitive performance in a 
number of domains, including fine motor tasks, the speed 
of response on attention and working memory tasks, and 
the accuracy of attention and short-term memory tasks 
[230].
5.2  Methylxanthines—Caffeine
In plants, caffeine is typically synthesised as the most 
prominent of a group of structurally related methylxan-
thines. However, controlled trials suggest that non-caffeine 
methylxanthines such as theobromine and theacrine, which 
is present in some tea plants, have inconsistent or negative 
effects on mood, and no interpretable beneficial effects 
on cognitive function [231–236]. Caffeine, on the other 
hand, has consistent central nervous system effects, rapid 
bioavailability, with a half-life of 3–5 h, and the propen-
sity to rapidly cross the blood-brain barrier [237]. Caf-
feine’s central nervous system effects at normal doses 
are predicated on its ability to inhibit the action of the 
inhibitory neuromodulator adenosine at adenosine  A1 and 
 A2 receptors distributed throughout the vasculature and 
neuronal tissue. The resultant release of inhibition leads 
to cerebral vasoconstriction and increased neuronal activ-
ity, with a net excitatory effect [238, 239]. Caffeine has 
well-established ergogenic properties and has been shown 
to enhance performance of both endurance exercise and 
high-intensity and intermittent exercise, for instance as 
associated with team sports. These benefits are attributed 
primarily to its effects on the central nervous system at 
moderate/high doses (~ 3–6 mg/kg or 225–450 mg for a 
75-kg individual) [7]. Lower doses of caffeine, in the range 
from 32 mg to 300 mg, have been shown to enhance brain 
function, with effects plateauing or attenuating at higher 
doses [237]. However, caffeine’s effects on psychologi-
cal function are limited to increased subjective arousal/
alertness, and improved performance of psychomotor tasks 
and ‘simple’ attention, focussed attention and vigilance 
type tasks. Caffeine has inconsistent effects on working 
memory and executive function tasks and no interpret-
able effect on memory function [237, 238, 240]. As with 
nicotine, the use of caffeine in a sporting context is com-
plicated by habituation and withdrawal.
5.2.1  Caffeine Interactions
Whilst it has been suggested that anhydrous caffeine may be 
more effective in terms of ergonenic benefits than coffee [7], 
a recent synthesis of the literature described good evidence 
that caffeine consumed in the form of coffee is also effective 
for improving performance during endurance exercise [241]. 
Evidence also suggests that caffeine may participate in addi-
tive or synergistic relationships when co-consumed with 
other bioactive compounds. For instance, the brain function 
effects of caffeine are differentially modulated, or vice versa, 
by the co-consumption of other phytochemicals [238], and 
food components such as amino acids [242–244], glucose 
[245, 246], choline[247], taurine [248, 249] and micronutri-
ents [250, 251]. Co-consumption of comparatively low doses 
of caffeine has also been shown to increase the bioavailabil-
ity of phenolic compounds [252, 253]. A recent study also 
showed that co-administration of caffeine/methylxanthines 
alongside cocoa-flavanols increased plasma flavanol metabo-
lites and led to greater cardiovascular effects than cocoa-fla-
vanols alone. Methylxanthines by themselves had no effect 
on any parameter [254]. This does raise the question of the 
potential synergistic contribution of caffeine to the effects of 
the cocoa-flavanol interventions employed in the numerous 
controlled trials that provide the bulk of the polyphenol lit-
erature (see Sect. 3.1). The interventions here typically con-
tain 15–40 mg of caffeine, with a methylxanthine-matched 
control treatment, but no flavanol-only comparator.
5.2.2  Caffeine—Guaraná (Paullinia cupana)
One example of potential caffeine/phytochemical inter-
actions is provided by guaraná (Paullinia cupana). The 
effects of guaraná seed extract are typically attributed to 
the presence of caffeine (2.5–5% dry weight). However, 
extracts also contain significant levels of polyphenols and 
triterpene saponins [255]. Controlled single-dose trials 
have shown that guaraná extract (75 mg) can improve atten-
tion, executive function and working memory tasks [200], 
and engender dose-related (37.5 mg, 75 mg, 150 mg and 
300 mg guaraná) increases in alertness, ‘contentedness’ and 
memory task performance. However, most of these effects 
have been seen following doses of guaraná that contain non-
psychoactive levels of caffeine (4.5 mg/9 mg) [255]. Single 
doses of multivitamin/minerals with added guaraná (220 mg 
including 40 mg of caffeine) have been shown to improve 
the performance of difficult attention and working memory 
tasks, alongside improvements in alertness or contentedness 
[250, 256], with mood benefits seen both before and after 
30 min of treadmill running at 60% of their maximal oxygen 
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consumption (VO2max) [257]. A study that compared a mul-
tivitamin/mineral plus guaraná to both placebo and its caf-
feine content found that guaraná improved executive func-
tion/attention task more than its caffeine content alone [258].
5.2.3  Conclusion
Courtesy of their ecological roles, which include the dis-
ruption of neurotransmission in herbivores, alkaloids have 
the most profound brain function effects amongst the phy-
tochemical groups. At the low doses usually consumed by 
humans, both nicotine and caffeine are capable of engen-
dering benefits to psychological functioning that could 
translate into performance benefits in a sporting context. 
However, these alkaloids are toxic at high doses, and they 
engender habituation via modulation of receptor popu-
lations and sensitivity, which could lead to symptoms of 
withdrawal, including potential performance decrements, in 
their absence. Nicotine is also highly addictive and therefore 
best avoided. The cognitive effects of these phytochemicals 
in a sporting context may therefore be most marked in those 
who either do not use these alkaloids regularly (for instance 
during training), or, particularly in the case of caffeine, when 
habitual consumption is low in comparison to the intended 
performance-enhancing dose. That having been said, a 
growing literature suggests that the co-consumption of com-
paratively low doses of caffeine alongside other bioactive 
compounds, for instance in the form of guaraná, may lead 
to additive or synergistic effects on cognitive performance 
and alertness.
6  Conclusion
A number of phytochemicals have cognitive and alertness/
arousal effects that may be relevant to improved sporting 
performance. Broadly, these effects can be related to the eco-
logical roles of the phytochemical groups. Phenolics and their 
polyphenol subgroup, which currently attract the most research 
attention, are intrinsic to good health and cardiovascular func-
tion as part of the everyday diet. However, the evidence of 
additional benefits to cognitive function and mood following 
short-term supplementation is currently weak. This profile of 
functional effects is in keeping with their plant roles as general 
protectants. On the other hand, the terpenes and alkaloids dis-
cussed above, which are not a natural, unavoidable component 
of the diet, serve ecological roles that include interactions with 
the central nervous systems of symbiotes and/or herbivores. 
Terpenes tend to be overlooked, but the evidence of beneficial 
cognitive and mood effects is promising for several edible, 
monoterpene-expressing herbs such as sage, rosemary and 
peppermint; diterpene-rich G. biloba; and several triterpene-
rich extracts, including ginseng and bacopa. Whilst research 
is lacking in some respects for all of these extracts, they are 
all safe and well tolerated, and none are associated with sig-
nificant negative effects on any parameter. Alkaloids, as the 
archetypal plant defence compounds, often have intense effects 
on neurotransmission in herbivores and human consumers. 
However, their potency, toxicity and legal status mean that 
only nicotine and caffeine currently have any obvious poten-
tial role in cognitive enhancement in a sporting context. How-
ever, nicotine is addictive, and the contribution of habitua-
tion and withdrawal effects, and therefore dosage patterns, for 
both compounds, need to be taken into consideration. Some 
interesting data are emerging with regard to potential additive 
effects and synergies when phytochemicals and low doses of 
caffeine are co-consumed, and phytochemical or nutrient-rich 
extracts containing low doses of caffeine might be a rational 
approach for enhancing cognitive function.
Whilst several of the phytochemicals reviewed above would 
seem to have potential utility in terms of improved cognitive 
function or psychological state in healthy adults, the current 
lack of direct evidence collected in a sporting context means 
that no firm recommendations are possible at this time. The 
efficacy of phytochemicals, in particular the benign phenolics 
and terpenes reviewed above, and the potential for positive, or 
indeed negative, interactive effects between their psychoactive 
properties and the physical and psychological arousal intrinsic 
to most sports deserves more research attention.
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